Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lupin Limited

http://www.lupin.com

Latest From Lupin Limited

Latuda Enters ‘Twilight’ Phase Pending Generic Competition

A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.

Generic Drugs Launches

Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival

Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.

Sales & Earnings Generic Drugs

India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.

India Commercial

Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League

Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.

Strategy Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • Nutraceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Pulmonary
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Other Names / Subsidiaries
    • Generic Health Pty Ltd
    • Temmler Pharma GmbH & Co.
    • YL Biologics (YLB)
    • ZAO Biocom
    • Kyowa Pharmaceutical Industry Co., Ltd.
    • Southern Cross Pharma Pty Ltd
    • Symbiomix Therapeutics, LLC.
UsernamePublicRestriction

Register